Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 5/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19600883 | 0.88 | HPGDS (0.43) | HDAC1HPGDSHRH3HDAC3HDAC10 | |
| SCHEMBL20076245 | 0.81 | HPGDS (0.56) | HDAC1HPGDSHDAC3HDAC10HDAC6 | |
| SCHEMBL22873387 | 0.78 | HPGDS (0.44) | HPGDSHRH3HDAC3HDAC10HDAC6 | |
| SCHEMBL29817233 | 0.78 | OGA (0.48) | HDAC1HRH3KMT2ANPC1RAB9A | |
| SCHEMBL19581011 | 0.78 | OGA (0.48) | HDAC1HRH3KMT2ANPC1RAB9A | |
| SCHEMBL20075923 | 0.78 | DDB1 (0.52) | HDAC1HRH3KMT2AUSP30 | |
| SCHEMBL23158449 | 0.77 | HPGDS (0.45) | HPGDSHRH3HDAC10HDAC6KMT2A | |
| SCHEMBL19581123 | 0.76 | AR (0.60) | — | |
| SCHEMBL19581121 | 0.76 | AR (0.60) | — | |
| SCHEMBL19600790 | 0.75 | HPGDS (0.50) | HDAC1HPGDSHDAC3HDAC10HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, MDM2, ESRRA | HDAC1 500/4885HPGDS 2344/4885HRH3 3784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.